

PUBLISHED IN

The Journal of Urology

August 2018

Study Title: THREE-YEAR TREATMENT OUTCOMES OF WATER VAPOR THERMAL THERAPY COMPARED TO DOXAZOSIN, FINASTERIDE AND COMBINATION DRUG THERAPY IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: COHORT DATA FROM THE MTOPS TRIAL

Author Block: Nikhil Gupta, Tyson Rogers, Bradley Holland, Sevann Helo, Danuta Dynda and Kevin T. McVary

Purpose

We evaluated the long-term outcomes of treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) to compare a one-time water vapor thermal therapy procedure with daily medical therapy in cohorts from the MTOPS (Medical Therapy of Prostatic Symptoms) study.

Materials and Methods

Results in the treatment arm of a randomized, controlled trial of thermal therapy using the Rezūm™ System were compared to MTOPS subjects treated with doxazosin and/or finasteride. Evaluations were restricted to medical therapy subjects, representing 1,140 of the original 3,047 (37.4%), with a prostate volume of 30 to 80 cc and an International Prostate Symptom Score of 13 or greater to include men who met key criteria of the Rezūm and MTOPS trials. Outcomes were compared during 3 years for symptom changes and clinical progression rates.

Results

Thermal therapy improved symptom scores by approximately 50% throughout 36 months ($p < 0.0001$). Symptom improvement was greater than with either drug alone but similar to that of combination drugs ($p \leq 0.02$ and 0.73 , respectively). The peak flow rate improved 4 to 5 ml per second after thermal therapy and doxazosin, while thermal therapy was superior to finasteride and combination drugs for 24 and 12 months ($p < 0.001$ and < 0.01 , respectively). Observed rates of clinical progression during 3 years corroborate these outcomes with approximately 5 times greater progression for any medical therapy vs. a single thermal therapy procedure.

Conclusions

A single water vapor thermal therapy procedure provided effective and durable improvements in symptom scores with lower observed clinical progression rates compared to daily long-term use of pharmaceutical agents.

Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for use only in countries with applicable health authority registrations. Material not intended for use in France.

Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. Please check availability with your local sales representative or customer service.

All trademarks are the property of their respective owners.

**Boston
Scientific**

Advancing science for life™

Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, MA 01752
www.bostonscientific.com

Ordering Information
1.888.272.1001

© 2019 Boston Scientific Corporation
or its affiliates. All rights reserved.

URO-579806-AA APR 2019

CE 0344